Source: Tony Dante
Organon & Co. (NYSE: OGN) Acquisition: Sun Pharma’s Strategic Move into Women’s Health and Biosimilars
In a significant development in the pharmaceutical industry, Organon & Co. (NYSE: OGN) is set to be acquired by Sun Pharmaceutical Industries for $14.00 per share in an all-cash deal. This acquisition values the global healthcare company at approximately $11.75 billion, marking a significant milestone for both companies. However, this deal has also raised eyebrows, with an investigation into potential undervaluation of Organon being launched.
Details of the Acquisition Deal
With this acquisition, Sun Pharmaceutical Industries is making a calculated move to strengthen and expand its global presence, particularly in the women’s health sector and biosimilars market. Following the announcement, Organon shares saw a surge of 17.01%, reflecting the market’s positive response to the deal. However, this transaction is not without controversy as it faces scrutiny from the law firm Johnson Fistel, which is questioning the board members of Organon regarding a potential undervaluation of the company.
About Organon & Co.
Organon & Co. is a leading global healthcare company that was previously a part of Merck & Co., Inc. (NYSE: MRK). The company primarily focuses on women’s health, developing and delivering various health solutions that cater to this demographic. Apart from women’s health, Organon’s business also includes a robust portfolio of established brands and biosimilars, which positions it competitively among other large pharmaceutical companies.
Investment Firm Ratings and the Implications of the Buyout
Prior to the acquisition announcement, on April 27, 2026, investment firm Piper Sandler Companies (NYSE: PIPR) upgraded Organon to a Neutral rating from its previous Underweight grade. The stock price was $13.18 at the time of the new rating. This upgrade coincided with the major announcement of the company buyout, indicating a shift in market perception for Organon.
The acquisition by India’s Sun Pharmaceutical Industries agrees to acquire Organon for $14.00 per share in an all-cash deal, which sent Organon shares surging 17.01% to $13.18. This significant leap in share price signifies an enterprise value of approximately $11.75 billion for Organon.
Legal Scrutiny and the Future Prospects of the Deal
While the deal is viewed as a strategic move by Sun Pharmaceutical Industries, it has not been without its share of scrutiny. Legal firm Johnson Fistel has launched an investigation into the board members of Organon, questioning whether they failed in their duties by accepting an offer that may undervalue the company. The outcome of this investigation could have implications on the finalization of the deal.
For Sun Pharmaceutical Industries, this acquisition is a major step in expanding its global reach. As pointed out by financial experts at Zacks, the deal enables Sun Pharma to grow in the women’s health sector and provides a significant entry into the biosimilars market. This strategic move positions Sun Pharma for potential growth and diversification in these specialized markets. The transaction is expected to close in early 2027, signaling a promising start for Sun Pharmaceutical Industries in these sectors.
In conclusion, this acquisition represents a significant shift in the pharmaceutical landscape, with potential continued growth for Sun Pharmaceutical Industries in the women’s health sector and the biosimilars market. However, the investigation into potential undervaluation of Organon adds a layer of uncertainty to the deal, which stakeholders will be watching closely.